Helus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder [Yahoo! Finance]
Helus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder
Cybin (HELP) had its price target raised by HC Wainwright from $55.00 to $95.00. They now have a "buy" rating on the stock.
Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments [Globe and Mail, The (Toronto, Canada)]
Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders [Globe and Mail, The (Toronto, Canada)]